Ascend Wellness Holdings (AAWH) Cash from Financing Activities (2020 - 2026)
Ascend Wellness Holdings (AAWH) posted quarterly Cash from Financing Activities of -$592000.0 for Q1 2026, down 104.32% year-over-year from $13.7 million in Q1 2025, and up 48.48% quarter-over-quarter from -$1.1 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$592000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 104.32% year-over-year to -$592000.0; the TTM figure through Mar 2026 stood at -$9.2 million (down 78.29% YoY), while the FY2025 annual figure was $5.1 million, up 125.09% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$592000.0, up from -$1.1 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $54.7 million in Q2 2022, with the low at -$14.0 million in Q2 2025.
- The 5-year median for Cash from Financing Activities is -$1.1 million (2025), against an average of $2.3 million.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities soared 1070.0% in 2022, then slumped 6947.95% in 2024.
- Ascend Wellness Holdings' Cash from Financing Activities stood at $18.5 million in 2022, then slumped by 99.61% to $73000.0 in 2023, then plunged by 6947.95% to -$5.0 million in 2024, then soared by 77.02% to -$1.1 million in 2025, then soared by 48.48% to -$592000.0 in 2026.
- Business Quant data shows AAWH's Cash from Financing Activities at -$592000.0 in Q1 2026, -$1.1 million in Q4 2025, and $6.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Ascend Wellness Holdings | 97.42 Mn | 30.42 Mn | 45.49 Mn | -3.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.28 Mn |
| Jun 30, 2026 | -3.28 Mn |
| Mar 31, 2026 | -592,000.00 |
| Mar 31, 2026 | -592,000.00 |
| Dec 31, 2025 | -1.15 Mn |
| Dec 31, 2025 | -1.15 Mn |
| Sep 30, 2025 | 6.54 Mn |
| Sep 30, 2025 | 6.54 Mn |
| Jun 30, 2025 | -13.98 Mn |
| Jun 30, 2025 | -13.98 Mn |
| Mar 31, 2025 | 13.69 Mn |
| Mar 31, 2025 | 13.69 Mn |
| Dec 31, 2024 | -5.00 Mn |
| Dec 31, 2024 | -5.00 Mn |
| Sep 30, 2024 | -9.27 Mn |
| Sep 30, 2024 | -9.27 Mn |
| Jun 30, 2024 | -4.57 Mn |
| Jun 30, 2024 | -4.57 Mn |
| Mar 31, 2024 | -1.52 Mn |
| Mar 31, 2024 | -1.52 Mn |